# Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

> **NCT04657822** · PHASE4 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 130 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Crizanlizumab

## Key facts

- **NCT ID:** NCT04657822
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-10
- **Primary completion:** 2031-06-10
- **Final completion:** 2031-06-10
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657822, "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04657822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*